New Break Discusses Fresh Collaborative Approach to Exploring the Moray Property Ludwig Files A Patent That Could Be a Major Technology Breakthrough in Healthcare SFLMaven: New NFT Metaverse Jewelry Pieces to Be Released in Q3 2022 PSYC's Spotlight Media Corp to Host MJBizCon Kickoff Party at Brooklyn Bowl Las Vegas TRU Opens Up New Copper-Gold-Silver Discovery at Golden Rose Sells Out Its Water Bear PFP Mint In Only 45 Minutes With The Premiere of The Genesis Collections ResGreeen Uses Open-Source Robot Operating System (ROS) to Enhance Integration and Simulation for LilBuddy AMR īranded Legacy, Inc. HealthLynked Announces Upgrades to its MedOfficeDirect Ecommerce Site for Discount Medical Supplies It is also listed on the Patent as the co-owner along with Transplantation Limited. The company is called Fission Biomedical LLC. Casey has registered a new company in 2017 in the State of Kentucky. THE BIGGEST INTRIGUING NEWS IS THIS RECENT ACTIVITY: Dr. THIS YEAR In 2018, he applied for another new patent: In 2017 Casey was granted another NEW patent : Patrick Casey, who owns 3,000,000 preferred C shares via Therapy Cells, Limited (New Zealand) is also one of three beneficiary stockholders in Therapy Cells, Inc. in past PR stated that this was a long term funding agreement - as research is not a Fast process but an approach to science that requires tenacity and hard work, and the funding matter has to be out of the way which it has been during this time of dedicated silence in our opinion:ĭr. Some NEW good news, just out last month from Sofinnova Partners, is that they have new funding for Biotech and Pharmaceutical companies estimated to be at least $375 million. The company has been quietly completing their research since! It's possible there were delays in receiving some of the funding, since it was coming from overseas (Paris), and it likely gets received as needed. The funding was in place in September 2015 via Soffinova Partners: In 2013, the company had to cease trials due to lack of funding. #Tcel reverse merger licensehas been granted exclusive license to use Patent 8372644 for use in human applications. (USA ) in August of 2011 for 3,000,000 Preferred C shares. Patrick Casey, Therapy Cells Limited (TCL), a New Zealand Corporation, was acquired by Therapy Cells Inc. Their primary business focus and direction is applying Patent 8372644 and pursuing Therapy Cell related business. Below is the research that would explain the current stock action and resurgence of volume and accumulation interest: Casey's new company which shares TCEL Patents into the company as well maybe as an acquisition or Reverse Merger. The Reinstatement also suggests that along with all these new developments, there is news on the horizon of possible FDA approval for human trials for Therapy Cells & the possibility and bringing Mr. #Tcel reverse merger fullCasey has been going full speed ahead behind the scenes. The recent stock activity of TCEL coupled to the recent reinstatement of TCEL with Wyoming SOS, along with WE HAVE UNCOVERED BRAND NEW PATENTS & A BRAND NEW COMPANY (Fission Biomedical LLC and ContraVaccine LTD.) Strongly Suggesting that the research by Dr.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |